Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104232597 | 10423259 | 7 | F | 20140203 | 20160902 | 20140902 | 20160929 | PER | US-JNJFOC-20140827129 | JANSSEN | 5.77 | YR | C | M | Y | 0.00000 | 20160929 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104232597 | 10423259 | 1 | SS | RISPERDAL | RISPERIDONE | 1 | Oral | N | U | 0 | SOLUTION | ||||||||
| 104232597 | 10423259 | 2 | SS | RISPERDAL | RISPERIDONE | 1 | Oral | N | U | 0 | SOLUTION | ||||||||
| 104232597 | 10423259 | 3 | PS | RISPERDAL | RISPERIDONE | 1 | Oral | N | U | 20588 | SOLUTION | ||||||||
| 104232597 | 10423259 | 4 | SS | RISPERDAL | RISPERIDONE | 1 | U | U | 20272 | UNSPECIFIED | |||||||||
| 104232597 | 10423259 | 5 | SS | RISPERIDONE. | RISPERIDONE | 1 | Unknown | U | 0 | SOLUTION | |||||||||
| 104232597 | 10423259 | 6 | SS | INVEGA | PALIPERIDONE | 1 | Oral | N | U | 0 | 1.5 | MG | OROS (ORAL OSMOTIC) THERAPEUTIC SYSTEM TABLET | ||||||
| 104232597 | 10423259 | 7 | SS | INVEGA | PALIPERIDONE | 1 | Oral | N | U | 21999 | 1.5 | MG | OROS (ORAL OSMOTIC) THERAPEUTIC SYSTEM TABLET | ||||||
| 104232597 | 10423259 | 8 | C | CLONIDINE. | CLONIDINE | 1 | Unknown | 0.1 TO 0.2 MG | D | 0 | UNSPECIFIED | ||||||||
| 104232597 | 10423259 | 9 | C | TRILEPTAL | OXCARBAZEPINE | 1 | Unknown | D | 0 | UNSPECIFIED | |||||||||
| 104232597 | 10423259 | 10 | C | INTUNIV | GUANFACINE HYDROCHLORIDE | 1 | Unknown | D | 0 | 3 | MG | UNSPECIFIED | |||||||
| 104232597 | 10423259 | 11 | C | PROZAC | FLUOXETINE HYDROCHLORIDE | 1 | Unknown | D | 0 | UNSPECIFIED | |||||||||
| 104232597 | 10423259 | 12 | C | CLONAZEPAM. | CLONAZEPAM | 1 | Unknown | D | 0 | .25 | MG | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 104232597 | 10423259 | 1 | Aggression |
| 104232597 | 10423259 | 2 | Attention deficit/hyperactivity disorder |
| 104232597 | 10423259 | 3 | Autism |
| 104232597 | 10423259 | 4 | Product used for unknown indication |
| 104232597 | 10423259 | 5 | Product used for unknown indication |
| 104232597 | 10423259 | 6 | Affective disorder |
| 104232597 | 10423259 | 7 | Attention deficit/hyperactivity disorder |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 104232597 | 10423259 | Abnormal weight gain | |
| 104232597 | 10423259 | Blood triglycerides increased | |
| 104232597 | 10423259 | Depression | |
| 104232597 | 10423259 | Gynaecomastia | |
| 104232597 | 10423259 | Hyperlipidaemia | |
| 104232597 | 10423259 | Hyperprolactinaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 104232597 | 10423259 | 1 | 2012 | 201602 | 0 | |
| 104232597 | 10423259 | 2 | 2012 | 201602 | 0 | |
| 104232597 | 10423259 | 3 | 2012 | 201602 | 0 | |
| 104232597 | 10423259 | 6 | 20110322 | 201104 | 0 | |
| 104232597 | 10423259 | 7 | 20110322 | 201104 | 0 | |
| 104232597 | 10423259 | 8 | 2011 | 0 | ||
| 104232597 | 10423259 | 9 | 2011 | 2014 | 0 | |
| 104232597 | 10423259 | 10 | 2013 | 0 | ||
| 104232597 | 10423259 | 11 | 2014 | 2015 | 0 | |
| 104232597 | 10423259 | 12 | 2015 | 2016 | 0 |